203 related articles for article (PubMed ID: 35843864)
1. Prognostic Role of RNA Expression Molecular Biomarkers in Prostate and Bladder Cancers.
Ahmed ME; Todenhöfer T; Karnes RJ; Seiler R
Eur Urol Focus; 2022 May; 8(3):663-666. PubMed ID: 35843864
[TBL] [Abstract][Full Text] [Related]
2. Transcript analysis of commercial prostate cancer risk stratification panels in hard-to-predict grade group 2-4 prostate cancers.
Lehto TK; Stürenberg C; Malén A; Erickson AM; Koistinen H; Mills IG; Rannikko A; Mirtti T
Prostate; 2021 May; 81(7):368-376. PubMed ID: 33734461
[TBL] [Abstract][Full Text] [Related]
3. Genomic Markers in Prostate Cancer Decision Making.
Cucchiara V; Cooperberg MR; Dall'Era M; Lin DW; Montorsi F; Schalken JA; Evans CP
Eur Urol; 2018 Apr; 73(4):572-582. PubMed ID: 29129398
[TBL] [Abstract][Full Text] [Related]
4. Commercial Gene Expression Tests for Prostate Cancer Prognosis Provide Paradoxical Estimates of Race-Specific Risk.
Creed JH; Berglund AE; Rounbehler RJ; Awasthi S; Cleveland JL; Park JY; Yamoah K; Gerke TA
Cancer Epidemiol Biomarkers Prev; 2020 Jan; 29(1):246-253. PubMed ID: 31757784
[TBL] [Abstract][Full Text] [Related]
5. Long noncoding RNA in prostate, bladder, and kidney cancer.
Martens-Uzunova ES; Böttcher R; Croce CM; Jenster G; Visakorpi T; Calin GA
Eur Urol; 2014 Jun; 65(6):1140-51. PubMed ID: 24373479
[TBL] [Abstract][Full Text] [Related]
6. Urine microRNAs as potential noninvasive biomarkers in urologic cancers.
Mlcochova H; Hezova R; Stanik M; Slaby O
Urol Oncol; 2014 Jan; 32(1):41.e1-9. PubMed ID: 24035473
[TBL] [Abstract][Full Text] [Related]
7. Biomarkers in prostate cancer: what's new?
Sartori DA; Chan DW
Curr Opin Oncol; 2014 May; 26(3):259-64. PubMed ID: 24626128
[TBL] [Abstract][Full Text] [Related]
8. A Rich Array of Prostate Cancer Molecular Biomarkers: Opportunities and Challenges.
Kohaar I; Petrovics G; Srivastava S
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31013716
[TBL] [Abstract][Full Text] [Related]
9. Genomic Predictors of Outcome in Prostate Cancer.
Boström PJ; Bjartell AS; Catto JW; Eggener SE; Lilja H; Loeb S; Schalken J; Schlomm T; Cooperberg MR
Eur Urol; 2015 Dec; 68(6):1033-44. PubMed ID: 25913390
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Biomarkers Used for Localised Prostate Cancer Management: A Systematic Review.
Lamy PJ; Allory Y; Gauchez AS; Asselain B; Beuzeboc P; de Cremoux P; Fontugne J; Georges A; Hennequin C; Lehmann-Che J; Massard C; Millet I; Murez T; Schlageter MH; Rouvière O; Kassab-Chahmi D; Rozet F; Descotes JL; Rébillard X
Eur Urol Focus; 2018 Dec; 4(6):790-803. PubMed ID: 28753865
[TBL] [Abstract][Full Text] [Related]
11. Prostate cancer genomics: comparing results from three molecular assays.
Alam S; Tortora J; Staff I; McLaughlin T; Wagner J
Can J Urol; 2019 Jun; 26(3):9758-9762. PubMed ID: 31180305
[TBL] [Abstract][Full Text] [Related]
12. Clinically available RNA profiling tests of prostate tumors: utility and comparison.
Na R; Wu Y; Ding Q; Xu J
Asian J Androl; 2016; 18(4):575-9. PubMed ID: 26975490
[TBL] [Abstract][Full Text] [Related]
13. New Histopathological & Genetic Features to Improve Active Surveillance Selection for Low-Risk Prostate Cancer.
Chu K; Corcoran N; Norden S; Wong LM
Anticancer Agents Med Chem; 2018; 18(7):951-957. PubMed ID: 29141559
[TBL] [Abstract][Full Text] [Related]
14. Incorporation of tissue-based genomic biomarkers into localized prostate cancer clinics.
Moschini M; Spahn M; Mattei A; Cheville J; Karnes RJ
BMC Med; 2016 Apr; 14():67. PubMed ID: 27044421
[TBL] [Abstract][Full Text] [Related]
15. Are localized prostate cancer biomarkers useful in the clinical practice?
Carneiro A; Priante Kayano P; Gomes Barbosa ÁR; Langer Wroclawski M; Ko Chen C; Cavlini GC; Reche GJ; Sanchez-Salas R; Tobias-Machado M; Sowalsky AG; Bianco B
Tumour Biol; 2018 Sep; 40(9):1010428318799255. PubMed ID: 30204063
[TBL] [Abstract][Full Text] [Related]
16. Prognostic and predictive miRNA biomarkers in bladder, kidney and prostate cancer: Where do we stand in biomarker development?
Schubert M; Junker K; Heinzelmann J
J Cancer Res Clin Oncol; 2016 Aug; 142(8):1673-95. PubMed ID: 26660324
[TBL] [Abstract][Full Text] [Related]
17. Emerging genomic biomarkers for improving kidney, prostate, and bladder cancer health disparities outcomes.
Mitchell KA; Williams H
Urol Oncol; 2022 Apr; 40(4):126-132. PubMed ID: 31239186
[TBL] [Abstract][Full Text] [Related]
18. Novel biomarkers and genomic tests in prostate cancer: a critical analysis.
Falzarano SM; Ferro M; Bollito E; Klein EA; Carrieri G; Magi-Galluzzi C
Minerva Urol Nefrol; 2015 Sep; 67(3):211-31. PubMed ID: 26054411
[TBL] [Abstract][Full Text] [Related]
19. Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline.
Eggener SE; Rumble RB; Armstrong AJ; Morgan TM; Crispino T; Cornford P; van der Kwast T; Grignon DJ; Rai AJ; Agarwal N; Klein EA; Den RB; Beltran H
J Clin Oncol; 2020 May; 38(13):1474-1494. PubMed ID: 31829902
[TBL] [Abstract][Full Text] [Related]
20. miR-21-5p, miR-141-3p, and miR-205-5p levels in urine-promising biomarkers for the identification of prostate and bladder cancer.
Ghorbanmehr N; Gharbi S; Korsching E; Tavallaei M; Einollahi B; Mowla SJ
Prostate; 2019 Jan; 79(1):88-95. PubMed ID: 30194772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
